Mobile App

Google Play Apple Store
Talking Cardiovascular Disease Prevention: Emerging Strategies to Address Management Challenges in Dyslipidemia
AMA/ABS/ANCC/ACPE Activity
Dyslipidemia is a well-known risk factor for the development of cardiovascular disease, a leading cause of morbidity and mortality. Treatment of dyslipidemia represents one of the most crucial strategies to reduce risk of atherosclerotic cardiovascular (CV) disease (ASCVD). In this webcast archive, Dr. Deepak Bhatt and Dr. R. Scott Wright discuss recent clinical trial evidence for CV risk reduction with cholesterol-lowering therapies, with a focus on CV outcomes trials with current and emerging therapies that target proprotein convertase subtilisin/kexin type 9 (PCSK9).
Review the activity and claim AMA/ABS/ANCC/ACPE credit/contact hour after completion of a brief pretest and posttest/evaluation.




R. Scott Wright, MD R. Scott Wright, MD, FACC, FESC, FAHA
Professor of Medicine
Consultant in Cardiology
Mayo Clinic

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI Deepak L. Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI
Director
Mount Sinai Fuster Heart Hospital
Dr. Valentin Fuster Professor of Cardiovascular Medicine
Icahn School of Medicine at Mount Sinai

20
Supported by an independent educational grant from
Novartis Pharmaceuticals Corporation

Launch Date: February 13, 2024
Release Date: January 29, 2024
Expiration Date: January 31, 2025

Mini Module
7690
TalkingCVD_MiniModules(1730x162).png
Cardiology